Type 1 Diabetes (T1D) Market Size Worth USD 25.52 Billion By 2024

October 2, 2017

The global type 1 diabetes market is expected to reach USD 25.52 billion by 2024. A significant increase in the prevalence of type 1 diabetes coupled with Rigorous research & development activities to introduce novel formulations drives the T1D market growth.

Sedentary lifestyles, unhealthy diet habits coupled with rising obesity rates will further enhance the uptake of various types of insulin for the treatment of this disorder. Though this type of diabetes is rare still the number of cases is increasing by 3% every year according to the data enumerated by the International Diabetes Federation (IDF).

Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. This affects the respective countries and their national healthcare systems. For instance, the expenditure on diabetes management accounts for around 5% to 20% of the total healthcare spending.

Rapid-acting, long-acting and premix analogs are the three major types of insulin analogs administered to the patients. These insulin types when delivered duplicate the action of natural insulin and avoid the excess release of glucose in blood cells. The market penetration of long-acting insulin products is higher as compared to other two types, however, during the forecast period, the uptake and acceptance of rapid and premix analogs are anticipated to increase. The reason being the quick action and optimum performance of these two over long-acting insulin.

The insulin analogs market is consolidated in nature as three companies account for more than 50% of the total market share. The reason being extensive product offerings and continuous research and development activities. This market is witnessing an ongoing patent erosion affecting the market sustainability of companies. Also, high probability of launch of several biosimilars by new entrants, major players might face competition during the forecast period.

To enhance the overall sustainability, established players such as Novo Nordisk, Sanofi, and Eli Lilly are continuously investing in the development of the improved versions of insulin products. For instance, recent launches by Novo Nordisk (Xultophy, Tresiba) and Sanofi's Toujeo (improved version of Lantus). These factors exhibit the promising growth for type 1 diabetes treatment market.

Access full report or request for free sample at: https://www.hexaresearch.com/research-report/type-1-diabetes-t1d-market

Hexa Research has segmented the global type 1 diabetes (T1D) market based on insulin analog, and region:

Segmentation by insulin analog, 2014 - 2024 (USD Million)
• Rapid acting
• Long acting
• Premix analogs

Segmentation by region, 2014 - 2024 (USD Million)
• North America
    • U.S.
• Europe
    • UK
• Asia Pacific
    • China
    • India
• Rest of the world

Key players analyzed
• ADOCIA
• Biocon
• Bioton
• Eli Lilly and Company
• Novo Nordisk
• Sanofi
• Wockhardt

To schedule a free analyst call, please complete the form below.
Customer Service
  • Global Headquarters
  • Address: Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018‏ United States
  • Phone: +1-800-489-3075
  • [email protected]
  • Asia Pacific
  • Address: Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016 India
  • Phone: +91-20-65201091
  • [email protected]